MedTrace Logo

Study of SAB-176 in Healthy Adult Participants

NCT04850898 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2025-01-22

Study results available
· View outcomes & findings →

Summary

Healthy adult participants will be challenged with the H1N1 Influenza virus and then treated with either SAB-176 or placebo.

Conditions

  • Influenza A H1N1

Interventions

BIOLOGICAL

SAB-176

Treatment of influenza

OTHER

Placebo

Placebo Control

Sponsors & Collaborators

  • Hvivo

    collaborator INDUSTRY

  • SAb Biotherapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Victoria Parker · hVIVO Services Limited

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-06-23
Primary Completion
2021-10-08
Completion
2021-10-08
FDA Drug
Yes

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04850898 on ClinicalTrials.gov